Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.
Carlo Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Pfizer
Honoraria - Nadirex; Pfizer
Research Funding - Pfizer
Tim H. Brummendorf
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Jeffrey H. Lipton
No relevant relationships to disclose
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Eric Leip
Employment or Leadership Position - Pfizer
Kathleen Wyant Turnbull
Employment or Leadership Position - Pfizer
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer